Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| As I mentioned earlier, I'm encouraged by the progress we've made a really strong start to the year from development, regulatory and operational perspectives |
| We've made excellent progress building our capabilities and team |
| We've been able to, I think, very successfully execute the EMERGENT program, which includes both inpatient and outpatient studies in EMERGENT-4 and EMERGENT-5 that have recruited well, as noted by the support they'll provide for NDA submissions here next quarter |
| We're well positioned and well capitalized with the management team and in-house expertise needed to execute against our three strategic priorities, and I look forward to providing future updates across our programs and business |
| And so if coverage for a D2 antagonist can be secured, which is a one of 12 market, I think there's a strong likelihood that we're going to be able to achieve access for physicians and patients at a price that does not create budget problems for the payers and at the same time, rewards Karuna for its innovation |
| As we sit here today on May 4th, I can say, we've made excellent progress in all three areas |
| In the first quarter, we announced positive data from EMERGENT-3, our third consecutive positive efficacy and safety trial evaluating KarXT and schizophrenia |
| But I think we are encouraged when you look across the arc of all information that's available to us to date around xanomeline and KarXT from the biological rationale to the preclinical data, to the data from historical studies with xanomeline in Alzheimer's and schizophrenia and the studies with KarXT as part of the EMERGENT program |
| So I think we feel good about that from a regulatory perspective |
| The totality of the data generated to date reinforces the potential of KarXT to be a completely new and differentiated pharmacological treatment of schizophrenia that should be very well received by the psychiatry community if approved |
| But out of the gate, as I think about creating value with KarXT, I think the data set that we have here is pretty impressive |
| On the regulatory front, we had a positive pre-NDA meeting with the FDA this quarter, which reinforced our key assumptions related to our data package and timing, and we continue to target our NDA submission for the third quarter of this year |
| We're encouraged by what we see |
| It was very positive and productive meeting |
| We're encouraged by the results across those groups |
| We can do more than one thing at a time, but our single focus right now is ensuring that the NDA is submitted on time and it's at the highest quality |
| I think it should be positive |
| I would say that the initial reaction is a positive one |
| The first is to build the core, which means maximizing the value of KarXT through our continued development efforts, submitting the NDA in the third quarter, securing FDA approval and successfully launching KarXT in 2024 |
| Bill Meury And I would add that there's still a balanced conversation or dialogue between the companies and the payers in the area of mental health, which I think is a real positive |
| We think the two of those provide a really nice complement to each other |
| And so I think the initial signs are encouraging, but it will be put in the context of the total clinical profile, et cetera |
| We initiated the trial in April and are very pleased by our enrollment numbers to date, and we expect top line data in the fourth quarter of this year |
| I'll just define positive as it's simply -- the meeting simply reinforced the key assumptions that we had for preparing the NDA and then for submitting it in the third quarter of 2023 |
| But net-net, I believe, it was a positive |
| And to the extent we're able to do that, which we certainly have confidence in, that will establish a potential opportunity for an LAI formulation |
| And we, of course, through the EMERGENT program of dose KarXT and 1,500 patients and have three very convincing efficacy and safety trials |
| We think that's more than sufficient amount of time to have a clinical response on KarXT given the results of EMERGENT-1, EMERGENT-2 and EMERGENT-3 as well as the original Lilly Alzheimer's study where you saw substantial benefits towards psychosis appearing as early as the first couple of weeks of treatment |
| But I think at first blush, scientifically, it's intuitive, and I think we have some nice data, albeit preclinical at this stage to support that idea |
| If they're using two D2 antagonists that are pharmacologically more similar than different, I think it's pretty clear here that the opportunity for the muscarinic class, we're going to lead the class is pretty significant |
| Statement |
|---|
| These side effects can be burdensome for patients and reduce compliance, leading to relapse and hospitalization and negatively impact overall treatment outcomes in schizophrenia and the lack of these side effects can be meaningful for patients |
| And I imagine the disruption in Eastern Europe is still challenging |
| Please refer to today's press release and our SEC filings for important risk factors that could cause our actual performance and results to differ materially from those expressed or implied in these forward-looking statements |
| Due to something that's of interest to us |
| But are there other structural dynamics that are posing headwinds on study recruitment? And then one quick follow-up |
| I will just say upfront, I think it's difficult to hide from the IRA if you're running a biopharma company of any size |
Please consider a small donation if you think this website provides you with relevant information